INTRODUCTION
How electrical and structural indices can be used to guide ablation for atrial fibrillation (AF) is hotly debated. A plethora of electrical indices have been proposed including complex fractionated atrial electrograms (CFAE), 1 electrogram dispersion, 2 dominant frequency, 3 voltage mapping, and various approaches to map drivers including focal impulse and rotor mapping, 4 Cartofinder, 5, 6 Acutus Medical, 7 Ablacon, 8 and body surface mapping 9, 10 (which may identify similar sites). 8, 11, 12 Anatomically, targets are primarily the PVs, but also left atrial appendage, 13 posterior wall, and other sites. What is missingand urgently needed-is a functional theme to rationalize indices, by directly comparing methods or by defining populations in whom some indices are particularly relevant.
COMPARING AF INDICES
In this issue of the Journal, Ammar-Busch et al. report a welcome study comparing electrical signatures of CFAE and rotational drivers in persistent AF. 14 The authors should be congratulated on their goal of identifying the most relevant or "dominant" AF sites from secondary or potentially false-positive sites. This question is central to ongoing efforts to improve targeted AF ablation. Recent meta-analyses show that AF driver ablation increases AF termination rates and potentially long-term success over PVI alone, yet with significant heterogeneity between studies. [15] [16] [17] One solution to reduce heterogeneity is to refine mapping. Prioritizing targets is important when AF maps reveal multiple potential drivers, as leaving critical AF regions suboptimally ablated may contribute to varying outcomes. Choosing another marker to confirm critical features is thus a natural step, and CFAE is attractive as it may signify slow conduction. 18 Other candidate features include sites of rate-related conduction slowing, 19 low voltage, electrogram dispersion, 2 or combinations of multiple panoramic AF mapping methods 11 which often agree. 11, 20 
LIMITATIONS OF STUDY
Limitations of this study reflect the selected electrical indices, mapping approach, and clinical endpoints. First, the role of CFAE has been questioned, 1 which could reflect their heterogeneous nature 21 ; this may be resolved in metrics such as electrogram dispersion. 2 Second, while electrocardiographic imaging has yielded promising clinical outcomes, 22 its spatial resolution has been reported as about one square centimeter 23 which may complicate correlation to CFAE areas.
Moreover, AF drivers mapped by endocardial methods are less related to CFAE, 24, 25 which may reflect a higher threshold for defining CFAE or other factors. Of course, no perfect AF mapping system yet exists and endocardial basket mapping, while sufficient for AF driver mapping, 26 may also produce false positives. Third, although termination reflects acute disruption of persistent AF, it remains a controversial endpoint for predicting long-term outcome, although metrics of AF cycle length prolongation or even abolition of PV activity 27, 28 are even less well supported. Finally, the current study does not prove that critical AF drivers exist only at sites of CFAE. This conclusion could be challenged by the retrospective nature of the study, how the N = 16 patients were chosen from the larger AFACART registry, that this criterion would "miss" 18% (2/11) of AF terminating drivers, and that this discounts the potential impact of earlier site ablation on ultimate AF termination.
CONCLUSION
The authors should be congratulated on this interesting study that refines our understanding of electrical indices for AF ablation by comparing AF drivers with CFAE sites. Studies should extend this work to additional mapping modalities, and ultimately aim to identify mechanistic fingerprints for different patient phenotypes to improve longterm outcome.
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